Dr. Payam Amini, MD

Dr. Amini practices at California Eye Specialists Medical Group Inc in Pasadena, California.

Dr. Amini's NPI, 1205036456, was assigned on July 24, 2007. Dr. Amini graduated from SUNY Upstate Medical University in 2007. Dr. Amini holds California license A107595.

Dr. Amini's primary practice is California Eye Specialists Medical Group Inc, at 2619 E Colorado Blvd, Pasadena, CA 91107 in Los Angeles County. The practice phone is (626) 793-4168.

Dr. Amini's primary practice is California Eye Specialists Medical Group Inc in Pasadena, California. Dmand AI also links Dr. Amini to 5 medical groups and 4 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amini practices, 4 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Amini's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Amini is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Amini is licensed in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Amini treats.

CMS data shows 7,605 Medicare services from Dr. Amini across 28 procedure codes in 2024, for 1,434 Medicare patients. Medicare paid $600,647 for them. Every service was in an office.

CMS counts 1,434 Medicare patients who saw Dr. Amini in 2024. The largest group is 65 to 74, with 646 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 56% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amini's median patient age at 68, with 55% women.

In 2024, Dr. Amini wrote 3,331 Medicare Part D claims for 815 patients. 60% of them were for generic drugs. CMS names the drug for 3,225 of them, across 26 drugs with 11 or more claims each, at $266,234 in total drug cost. In 2023, CMS named 2,414 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Amini for performance year 2024, reported individually. Dr. Amini accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amini as offering telehealth. CMS counts 22 procedures of cataract surgery by Dr. Amini, more than 47% of the clinicians it reports for that procedure.

Dmand AI links 5 papers to Dr. Amini in 2015. The most frequent topics are Nerve Fibers, Ophthalmoscopy and Retina. Dr. Amini's most frequent co-authors are William R. Freeman, MD, Isaac C. Ezon, MD and Joseph T. Nezgoda, MD.

CMS Open Payments shows 199 general payments to Dr. Amini from 32 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 69% of the total. Genentech, Inc. paid the most, $2,875. It also lists 1 research payment totaling $2,800 in 2017.

Dr. Amini graduated from SUNY Upstate Medical University in 2007.

Dr. Amini is in network with 21 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.